Gene: Pcdh9 (protocadherin 9) Rattus norvegicus
Analyze
Symbol:
Pcdh9
Name:
protocadherin 9
Description:
Predicted to have calcium ion binding activity. Involved in forebrain development. Predicted to localize to cell-cell contact zone; growth cone; and integral component of plasma membrane. Orthologous to human PCDH9 (protocadherin 9); INTERACTS WITH 1,2-dimethylhydrazine; 17alpha-ethynylestradiol; 2,2',4,4'-Tetrabromodiphenyl ether.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Also known as:
LOC306091; protocadherin-9
Orthologs:
Species
Gene symbol and name
Data Source
Assertion derived from
less info ...
Orthologs 1
Homo sapiens (human):
PCDH9 (protocadherin 9) HGNC
EggNOG, Ensembl, HomoloGene, Inparanoid, NCBI, OMA, OrthoDB, OrthoMCL, Panther, Treefam
Mus musculus (house mouse):
Pcdh9 (protocadherin 9) HGNC
Treefam, EggNOG, OrthoMCL, NCBI, OMA, HomoloGene, Inparanoid, Panther, OrthoDB, Ensembl
Chinchilla lanigera (long-tailed chinchilla):
Pcdh9 (protocadherin 9) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Pan paniscus (bonobo/pygmy chimpanzee):
PCDH9 (protocadherin 9) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Canis lupus familiaris (dog):
PCDH9 (protocadherin 9) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Ictidomys tridecemlineatus (thirteen-lined ground squirrel):
Pcdh9 (protocadherin 9) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Sus scrofa (pig):
PCDH9 (protocadherin 9) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Chlorocebus sabaeus (African green monkey):
PCDH9 (protocadherin 9) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Heterocephalus glaber (naked mole-rat):
Pcdh9 (protocadherin 9) Transitive Ortholog Pipeline
Transitive Ortholog Pipeline
Alliance orthologs 3
Homo sapiens (human):
PCDH9 (protocadherin 9)
Alliance
DIOPT (HGNC|Hieranoid|InParanoid|OrthoFinder|OrthoInspector|PANTHER)
Mus musculus (house mouse):
Pcdh9 (protocadherin 9)
Alliance
DIOPT (Hieranoid|InParanoid|OrthoFinder|OrthoInspector|PANTHER)
Latest Assembly:
Rnor_6.0 - RGSC Genome Assembly v6.0
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl Rnor_6.0 15 76,787,108 - 77,738,668 (-) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 15 77,733,402 - 77,736,892 (-) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 15 80,341,840 - 80,658,843 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 Rnor_5.0 15 80,956,263 - 81,286,488 (-) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 15 75,827,180 - 76,739,147 (-) NCBI RGSC3.4 rn4 RGSC3.4 RGSC_v3.1 15 75,842,960 - 76,753,010 (-) NCBI Celera 15 68,728,387 - 69,614,167 (-) NCBI Celera Cytogenetic Map 15 q21 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Imported Annotations - CTD
autism spectrum disorder ISO RGD:1314916 11554173 CTD Direct Evidence: marker/mechanism CTD PMID:18252227
Gene-Chemical Interaction Annotations
1,2-dimethylhydrazine multiple interactions EXP 6480464 [APC protein affects the susceptibility to 1, 2-Dimethylhydrazine] which results in decreased expression of PCDH9 mRNA CTD PMID:27840820 15-acetyldeoxynivalenol increases expression ISO RGD:1314916 6480464 15-acetyldeoxynivalenol results in increased expression of PCDH9 mRNA CTD PMID:23792671 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of PCDH9 mRNA CTD PMID:29097150 17beta-estradiol affects expression ISO RGD:1314916 6480464 Estradiol affects the expression of PCDH9 mRNA CTD PMID:22574217 17beta-estradiol multiple interactions ISO RGD:1314916 6480464 [Estradiol co-treated with Progesterone] results in increased expression of PCDH9 mRNA, [Estradiol co-treated with TGFB1 protein] results in increased expression of PCDH9 mRNA CTD PMID:20660070 , PMID:30165855 2,2',4,4',5,5'-hexachlorobiphenyl multiple interactions ISO RGD:1556980 6480464 [2 more ... CTD PMID:25510870 2,2',4,4'-Tetrabromodiphenyl ether decreases expression EXP 6480464 2 more ... CTD PMID:27291303 2,2',5,5'-tetrachlorobiphenyl multiple interactions ISO RGD:1556980 6480464 [2 more ... CTD PMID:25510870 4,4'-sulfonyldiphenol increases expression ISO RGD:1556980 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of PCDH9 mRNA CTD PMID:30951980 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of PCDH9 mRNA CTD PMID:24780913 aflatoxin B1 decreases expression ISO RGD:1314916 6480464 Aflatoxin B1 results in decreased expression of PCDH9 mRNA CTD PMID:22100608 aflatoxin B1 increases methylation ISO RGD:1314916 6480464 Aflatoxin B1 results in increased methylation of PCDH9 exon CTD PMID:30157460 aflatoxin B1 decreases methylation ISO RGD:1314916 6480464 Aflatoxin B1 results in decreased methylation of PCDH9 gene CTD PMID:27153756 aflatoxin B2 affects methylation ISO RGD:1314916 6480464 aflatoxin B2 affects the methylation of PCDH9 intron CTD PMID:30157460 all-trans-retinoic acid increases expression ISO RGD:1314916 6480464 Tretinoin results in increased expression of PCDH9 mRNA CTD PMID:21934132 , PMID:23724009 arsane affects methylation ISO RGD:1314916 6480464 Arsenic affects the methylation of PCDH9 gene CTD PMID:25304211 arsenic atom affects methylation ISO RGD:1314916 6480464 Arsenic affects the methylation of PCDH9 gene CTD PMID:25304211 arsenite(3-) multiple interactions ISO RGD:1556980 6480464 TRP53 protein affects the reaction [arsenite results in increased expression of PCDH9 mRNA] CTD PMID:18929588 arsenite(3-) increases expression ISO RGD:1556980 6480464 arsenite results in increased expression of PCDH9 mRNA CTD PMID:18929588 benzo[a]pyrene affects methylation ISO RGD:1314916 6480464 Benzo(a)pyrene affects the methylation of PCDH9 intron CTD PMID:30157460 benzo[a]pyrene diol epoxide I increases expression ISO RGD:1314916 6480464 7 more ... CTD PMID:20382639 benzo[e]pyrene increases methylation ISO RGD:1314916 6480464 benzo(e)pyrene results in increased methylation of PCDH9 exon, benzo(e)pyrene results in increased methylation of PCDH9 intron CTD PMID:30157460 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1314916 6480464 Diethylhexyl Phthalate results in decreased expression of PCDH9 mRNA CTD PMID:31163220 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of PCDH9 mRNA CTD PMID:25181051 bisphenol A increases expression ISO RGD:1556980 6480464 bisphenol A results in increased expression of PCDH9 mRNA CTD PMID:30951980 butanal decreases expression ISO RGD:1314916 6480464 butyraldehyde results in decreased expression of PCDH9 mRNA CTD PMID:26079696 cefaloridine decreases expression EXP 6480464 Cephaloridine results in decreased expression of PCDH9 mRNA CTD PMID:18500788 cisplatin increases expression ISO RGD:1314916 6480464 Cisplatin results in increased expression of PCDH9 mRNA CTD PMID:27392435 crocidolite asbestos decreases expression ISO RGD:1314916 6480464 Asbestos, Crocidolite results in decreased expression of PCDH9 mRNA CTD PMID:18687144 , PMID:29523930 crocidolite asbestos increases methylation ISO RGD:1314916 6480464 Asbestos, Crocidolite results in increased methylation of PCDH9 gene CTD PMID:29523930 CU-O LINKAGE decreases expression ISO RGD:1314916 6480464 cupric oxide results in decreased expression of PCDH9 mRNA CTD PMID:22077320 cyclosporin A decreases expression ISO RGD:1314916 6480464 Cyclosporine results in decreased expression of PCDH9 mRNA CTD PMID:20106945 , PMID:27989131 DDT decreases expression EXP 6480464 DDT results in decreased expression of PCDH9 mRNA CTD PMID:30207508 diethylstilbestrol increases expression EXP 6480464 Diethylstilbestrol results in increased expression of PCDH9 mRNA CTD PMID:17005392 dioxygen decreases expression ISO RGD:1314916 6480464 Oxygen deficiency results in decreased expression of PCDH9 mRNA CTD PMID:26516004 disodium selenite decreases expression ISO RGD:1556980 6480464 Sodium Selenite results in decreased expression of PCDH9 mRNA CTD PMID:23274088 dorsomorphin multiple interactions ISO RGD:1314916 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin increases expression ISO RGD:1314916 6480464 Doxorubicin results in increased expression of PCDH9 mRNA CTD PMID:29803840 entinostat decreases expression ISO RGD:1314916 6480464 entinostat results in decreased expression of PCDH9 mRNA CTD PMID:27188386 formaldehyde increases expression ISO RGD:1314916 6480464 Formaldehyde results in increased expression of PCDH9 mRNA CTD PMID:20655997 genistein decreases expression ISO RGD:1556980 6480464 Genistein results in decreased expression of PCDH9 mRNA CTD PMID:32186404 mercury dibromide increases expression ISO RGD:1314916 6480464 mercuric bromide results in increased expression of PCDH9 mRNA CTD PMID:26272509 methapyrilene increases methylation ISO RGD:1314916 6480464 Methapyrilene results in increased methylation of PCDH9 exon, Methapyrilene results in increased methylation of PCDH9 intron CTD PMID:30157460 methylisothiazolinone increases expression ISO RGD:1314916 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of PCDH9 mRNA CTD PMID:31629900 methylmercury chloride increases expression ISO RGD:1314916 6480464 methylmercuric chloride results in increased expression of PCDH9 mRNA CTD PMID:23179753 , PMID:28001369 N-methyl-4-phenylpyridinium decreases expression ISO RGD:1314916 6480464 1-Methyl-4-phenylpyridinium results in decreased expression of PCDH9 mRNA CTD PMID:24810058 nickel atom decreases expression ISO RGD:1314916 6480464 Nickel results in decreased expression of PCDH9 mRNA CTD PMID:25583101 pentanal decreases expression ISO RGD:1314916 6480464 pentanal results in decreased expression of PCDH9 mRNA CTD PMID:26079696 phenylmercury acetate increases expression ISO RGD:1314916 6480464 Phenylmercuric Acetate results in increased expression of PCDH9 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1314916 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH9 mRNA CTD PMID:27188386 pirinixic acid multiple interactions ISO RGD:1314916 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of PCDH9 mRNA CTD PMID:19710929 potassium dichromate decreases expression ISO RGD:1556980 6480464 Potassium Dichromate results in decreased expression of PCDH9 mRNA CTD PMID:23608068 progesterone multiple interactions ISO RGD:1314916 6480464 [Estradiol co-treated with Progesterone] results in increased expression of PCDH9 mRNA CTD PMID:20660070 SB 431542 multiple interactions ISO RGD:1314916 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 serpentine asbestos increases methylation ISO RGD:1314916 6480464 Asbestos, Serpentine results in increased methylation of PCDH9 gene CTD PMID:29523930 silicon dioxide decreases expression ISO RGD:1314916 6480464 Silicon Dioxide analog results in decreased expression of PCDH9 mRNA, Silicon Dioxide results in decreased expression of PCDH9 mRNA CTD PMID:22300531 , PMID:25895662 sodium arsenite affects methylation ISO RGD:1314916 6480464 sodium arsenite affects the methylation of PCDH9 gene CTD PMID:28589171 tert-butyl hydroperoxide decreases expression ISO RGD:1314916 6480464 tert-Butylhydroperoxide results in decreased expression of PCDH9 mRNA CTD PMID:15336504 trichostatin A increases expression ISO RGD:1314916 6480464 trichostatin A results in increased expression of PCDH9 mRNA CTD PMID:24935251 , PMID:26272509 trichostatin A multiple interactions ISO RGD:1314916 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH9 mRNA CTD PMID:27188386 tunicamycin increases expression ISO RGD:1556980 6480464 Tunicamycin results in increased expression of PCDH9 mRNA CTD PMID:17127020 urethane decreases expression ISO RGD:1314916 6480464 Urethane results in decreased expression of PCDH9 mRNA CTD PMID:28818685 valproic acid decreases methylation ISO RGD:1314916 6480464 Valproic Acid results in decreased methylation of PCDH9 gene CTD PMID:29154799 valproic acid decreases expression ISO RGD:1314916 6480464 Valproic Acid results in decreased expression of PCDH9 mRNA CTD PMID:29154799 valproic acid affects expression ISO RGD:1314916 6480464 Valproic Acid affects the expression of PCDH9 mRNA CTD PMID:25979313 valproic acid increases expression ISO RGD:1314916 6480464 Valproic Acid results in increased expression of PCDH9 mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO RGD:1314916 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH9 mRNA CTD PMID:27188386 vorinostat increases expression ISO RGD:1314916 6480464 vorinostat results in increased expression of PCDH9 mRNA CTD PMID:26272509
Gene Ontology Annotations
1331729 Rf42 Renal function QTL 42 3.071 kidney blood vessel physiology trait (VT:0100012) absolute change in renal blood flow rate (CMO:0001168) 15 18093208 81255430 Rat 61424 Scl1 Serum cholesterol level QTL 1 7.7 0.001 blood cholesterol amount (VT:0000180) serum total cholesterol level (CMO:0000363) 15 18513913 88036354 Rat 1578646 Bmd18 Bone mineral density QTL 18 5.2 femur mineral mass (VT:0010011) trabecular volumetric bone mineral density (CMO:0001729) 15 26381041 106550657 Rat 1578647 Bmd17 Bone mineral density QTL 17 4 femur mineral mass (VT:0010011) total volumetric bone mineral density (CMO:0001728) 15 26381041 106550657 Rat 1578660 Bss19 Bone structure and strength QTL 19 4.3 femur morphology trait (VT:0000559) bone trabecular cross-sectional area (CMO:0002311) 15 26381041 106550657 Rat 1582214 Stl21 Serum triglyceride level QTL 21 3.1 0.022 blood triglyceride amount (VT:0002644) serum triglyceride level (CMO:0000360) 15 33219101 89640841 Rat 1582227 Gluco30 Glucose level QTL 30 3.6 0.0003 blood glucose amount (VT:0000188) absolute change in blood glucose level area under curve (CMO:0002034) 15 33219101 89640841 Rat 1582228 Epfw3 Epididymal fat weight QTL 3 4.1 0.0002 epididymal fat pad mass (VT:0010421) epididymal fat pad weight to body weight ratio (CMO:0000658) 15 33219101 89640841 Rat 1582242 Gluco28 Glucose level QTL 28 3.3 0.0008 blood glucose amount (VT:0000188) blood glucose level area under curve (AUC) (CMO:0000350) 15 33219101 89640841 Rat 1582244 Bw79 Body weight QTL 79 4 0.0002 epididymal fat pad mass (VT:0010421) epididymal fat pad weight to body weight ratio (CMO:0000658) 15 33219101 89640841 Rat 2293686 Bmd36 Bone mineral density QTL 36 7.4 0.0001 femur strength trait (VT:0010010) femoral neck ultimate force (CMO:0001703) 15 39749557 79033707 Rat 2293691 Bmd37 Bone mineral density QTL 37 6.6 0.0001 femur strength trait (VT:0010010) femur total energy absorbed before break (CMO:0001677) 15 39749557 79033707 Rat 1598828 Glom14 Glomerulus QTL 14 2.5 kidney glomerulus morphology trait (VT:0005325) index of glomerular damage (CMO:0001135) 15 41068094 86068094 Rat 1300144 Rf23 Renal function QTL 23 3.61 renal blood flow trait (VT:2000006) absolute change in renal vascular resistance (CMO:0001900) 15 43097470 106550657 Rat 724545 Niddm54 Non-insulin dependent diabetes mellitus QTL 54 0.02 blood glucose amount (VT:0000188) blood glucose level area under curve (AUC) (CMO:0000350) 15 57528970 81263988 Rat 2317050 Aia24 Adjuvant induced arthritis QTL 24 2.06 joint integrity trait (VT:0010548) left rear ankle joint diameter (CMO:0002149) 15 59651151 81255430 Rat 1576315 Schws6 Schwannoma susceptibility QTL 6 0.0069 nervous system integrity trait (VT:0010566) post-insult time of death (CMO:0002005) 15 61447766 106447766 Rat 61477 Aia4 Adjuvant induced arthritis QTL 4 3 joint integrity trait (VT:0010548) joint inflammation composite score (CMO:0000919) 15 62596410 99372139 Rat 631516 Gluco31 Glucose level QTL 31 7 blood glucose amount (VT:0000188) blood glucose level (CMO:0000046) 15 62596410 103164962 Rat 631655 Bp126 Blood pressure QTL 126 4 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 15 65520564 110520564 Rat 2313080 Bss65 Bone structure and strength QTL 65 3.9 0.0001 long bone metaphysis morphology trait (VT:0000133) tibia midshaft total cross-sectional area (CMO:0001715) 15 68366508 81255430 Rat 731177 Uae26 Urinary albumin excretion QTL 26 2.4 0.025 urine albumin amount (VT:0002871) urine albumin excretion rate (CMO:0000757) 15 75527634 111246239 Rat 2300326 Plaw1 Placental weight QTL 1 15 0.005 placenta mass (VT:0004257) placenta wet weight (CMO:0002088) 15 75761024 109400896 Rat 724548 Niddm55 Non-insulin dependent diabetes mellitus QTL 55 0.02 blood glucose amount (VT:0000188) blood glucose level area under curve (AUC) (CMO:0000350) 15 75761216 81263843 Rat
Predicted Target Of
Count of predictions: 160 Count of miRNA genes: 125 Interacting mature miRNAs: 133 Transcripts: ENSRNOT00000057924 Prediction methods: Microtar, Miranda, Rnahybrid Result types: miRGate_prediction
Gene-Chemical Interaction Annotations
